Ophthalmology stories

Sep 21, 2026

Beacon Therapeutics' gene therapy succeeds in phase 2 trial for rare inherited eye disease

Beacon Therapeutics reported its experimental gene therapy improved low-light reading ability in a late-stage trial for X-linked retinitis pigmentosa (XLRP), a rare inherited eye disease that can cause blindness. The company succeeded where larger drugmakers including Johnson & Johnson and Biogen have failed.

Sep 21, 20262 sources

Jun 24, 2026

Ollin Biosciences Raises $330 Million for Late-Stage Eye Disease Drug Trials

Texas-based biotech Ollin Biosciences secured $330 million in funding to advance late-stage clinical studies of its experimental eye disease treatment, representing one of the largest recent funding rounds in ophthalmology.

Jun 24, 20262 sources

Apr 8, 2026

Smart Contact Lens Monitors Eye Pressure and Delivers Glaucoma Drugs in Preclinical Tests

Researchers at the Terasaki Institute for Biomedical Innovation developed a smart contact lens that combines real-time intraocular pressure monitoring with responsive drug delivery for glaucoma patients, showing promise in preclinical models.

Apr 8, 20262 sources

Virus from Seafood Jumps to Humans, Causing Chronic Eye Disease

A virus that typically infects marine animals such as shrimp and fish has jumped to humans and is causing chronic eye disease in some people, according to a study published in Nature Microbiology.

Apr 8, 20261 source

Top claims

▪Beacon Therapeutics Chief Executive Officer Lance Baldo stated that the company has a chronological advantage as the only company with a positive readout on its primary endpoint within a pivotal phase three study for X-linked retinitis pigmentosa
▪Beacon Therapeutics announced plans to hold discussions with global regulatory authorities regarding a marketing application submission based on the results of its 12-month trial of 85 male subjects with X-linked retinitis pigmentosa treated with its gene therapy, laru-zova
▪According to National Institutes of Health data, X-linked retinitis pigmentosa affects approximately 4 in 100,000 males across the United States and Europe, and currently has no approved treatments

Topics

Biotech innovation Clinical trials Drug Approval and Clinical Trials Gene therapy Pharma Lyme disease treatment Texas Wearables & health tracking Biomarkers & bloodwork testing Infectious Disease and Outbreaks

Related entities

Zoonotic disease China